Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Zidovudine tablets 300 mg Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

NCT00779233
View directory record Official record
Conditions
Healthy
Interventions
Zidovudine tablets 300 mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00112047
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

NCT00960622
View directory record Official record
Conditions
HIV
Interventions
Truvada, Combivir, Trizivir
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 7, 2026, 6:22 AM EDT
Terminated Phase 3 Interventional

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

NCT00650637
View directory record Official record
Conditions
Diarrhea
Interventions
Calcium Carbonate, nelfinavir, lamivudine, loperamide, Calcium carbonate not administered, lamivudine + zidovudine
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
View directory record Official record
Conditions
HIV Infection
Interventions
Atazanavir + Ritonavir + Combivir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zidovudine Under Fasting Conditions

NCT00602550
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/zidovudine, Efavirenz, Raltegravir
Drug
Lead sponsor
Westat
Other
Eligibility
16 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, PI, RTV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

NCT00528957
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir DF, Zidovudine, Stavudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 15 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 7, 2026, 6:22 AM EDT
Not listed Phase 4 Interventional

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00011895
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Not applicable Interventional

A Study of Two Anti-HIV Drug Combinations

NCT00002203
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

NCT02737046
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma, ATLL
Interventions
Belinostat, Zidovudine, Interferon-Alfa-2b, Pegylated Interferon-Alfa-2b, Lymphodepleting Therapy
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 7, 2026, 6:22 AM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zidovudine Under Fed Conditions

NCT00601562
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 7, 2026, 6:22 AM EDT
Completed Phase 4 Interventional

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610
View directory record Official record
Conditions
HIV Infection
Interventions
Nelfinavir mesylate, 625 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 7, 2026, 6:22 AM EDT